Detalhe da pesquisa
1.
Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.
Oncologist
; 26(1): e153-e163, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32918774
2.
ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.
Oncologist
; 22(12): 1444-1450, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29079636
3.
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
Blood
; 126(22): 2479-83, 2015 Nov 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26443624
4.
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients.
Nat Commun
; 10(1): 3722, 2019 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31427573
5.
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
J Clin Oncol
; 20(9): 2240-50, 2002 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11980995
6.
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
J Thorac Oncol
; 8(2): 229-37, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23328549
7.
Ambulatory electronic medical record payback analysis 7 years after implementation in a tertiary care county medical system.
AMIA Annu Symp Proc
; : 1000, 2007 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-18694099